Thus, therapeutic drugs that improve both FAO and MRC activity, and mitochondrial antioxidants such as glutathione, could effectively alleviate hepatic steatosis and oxidative damage of NAFLD [7]. The gene discussed is CD200; the disease is metabolic dysfunction-associated steatotic liver disease.